Harel Insurance Investments & Financial Services Ltd. Purchases Shares of 2,235 Spark Therapeutics Inc (ONCE)

Harel Insurance Investments & Financial Services Ltd. purchased a new stake in shares of Spark Therapeutics Inc (NASDAQ:ONCE) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 2,235 shares of the biotechnology company’s stock, valued at approximately $122,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Aperio Group LLC grew its position in Spark Therapeutics by 23.5% during the second quarter. Aperio Group LLC now owns 5,543 shares of the biotechnology company’s stock valued at $459,000 after purchasing an additional 1,056 shares in the last quarter. Tocqueville Asset Management L.P. grew its position in Spark Therapeutics by 2.7% during the second quarter. Tocqueville Asset Management L.P. now owns 41,225 shares of the biotechnology company’s stock valued at $3,412,000 after purchasing an additional 1,075 shares in the last quarter. Amalgamated Bank grew its position in Spark Therapeutics by 29.7% during the second quarter. Amalgamated Bank now owns 4,799 shares of the biotechnology company’s stock valued at $397,000 after purchasing an additional 1,100 shares in the last quarter. Capital Fund Management S.A. grew its position in Spark Therapeutics by 8.1% during the second quarter. Capital Fund Management S.A. now owns 15,379 shares of the biotechnology company’s stock valued at $1,273,000 after purchasing an additional 1,152 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY grew its position in Spark Therapeutics by 13.1% during the second quarter. Metropolitan Life Insurance Co. NY now owns 10,207 shares of the biotechnology company’s stock valued at $845,000 after purchasing an additional 1,180 shares in the last quarter.

ONCE stock opened at $44.99 on Thursday. Spark Therapeutics Inc has a 12 month low of $41.06 and a 12 month high of $96.59.

Spark Therapeutics (NASDAQ:ONCE) last posted its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.77) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.34). The business had revenue of $25.19 million during the quarter, compared to the consensus estimate of $29.44 million. Spark Therapeutics had a negative return on equity of 17.33% and a negative net margin of 185.46%. On average, equities research analysts forecast that Spark Therapeutics Inc will post -1.44 EPS for the current fiscal year.

ONCE has been the topic of a number of research analyst reports. Credit Suisse Group boosted their price objective on shares of Spark Therapeutics from $75.00 to $98.00 and gave the company an “outperform” rating in a research report on Monday, July 9th. Cantor Fitzgerald set a $103.00 price objective on shares of Spark Therapeutics and gave the company a “buy” rating in a research report on Monday, July 16th. Royal Bank of Canada downgraded shares of Spark Therapeutics from an “outperform” rating to a “sector perform” rating and set a $100.00 price objective on the stock. in a research report on Thursday, July 19th. ValuEngine downgraded shares of Spark Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 24th. Finally, Citigroup raised shares of Spark Therapeutics from a “neutral” rating to a “buy” rating in a research report on Tuesday, August 7th. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the company. Spark Therapeutics presently has an average rating of “Hold” and an average target price of $70.10.

Spark Therapeutics Profile

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

See Also: Cash Flow

Want to see what other hedge funds are holding ONCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spark Therapeutics Inc (NASDAQ:ONCE).

Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply